Table 2.
Ongoing clinical trials on immunotherapy and targeted therapy for metastatic pancreatic adenocarcinoma.
| ClinicalTrials.gov Identifier | Target | Drug | Population | Additional therapy | Treatment setting | Phase | Status * |
|---|---|---|---|---|---|---|---|
| NCT02395016 | EGFR | Nimotuzumab | KRAS wild-type metastatic PDAC | Gemcitabine | Fist-line | III | Unknown |
| NCT03140670 | PARP | Rucaparib | Advanced PDAC with a somatic or germline mutation of BRCA or PALB2 | None | Maintenance | II | Active, not recruiting |
| NCT04348045 | PARP | Olaparib | Metastatic PDAC with a somatic mutation of BRCA or with a mutation of KRAS | FOLFIRI (control arm) | Maintenance | II | Not yet recruiting |
| MEK | Selumetinib | ||||||
| PD-L1 | Durvalumab | ||||||
| NCT02465060 | ALK translocation | Crizotinib | ALK-translocated solid tumors | None | Second-line or more | II | Recruiting |
| NCT04410653 | NRG1 | Afatinib | NRG1-rearranged solid tumors | None | Second-line or more | II | Not yet recruiting |
| NCT03504423 | Mitochondrial metabolism | Devimistat (CPI-613) | Metastatic PDAC | FOLFIRINOX or modified FOLFIRINOX | First-line | III | Recruiting |
| NCT04447092 | PD-1 | Pembrolizumab | Advanced PDAC | Gemcitabine plus nab-paclitaxel or FOLFIRINOX | First-line | II | Not yet recruiting |
| NCT03190265 | Combination immunotherapy | Nivolumab; ipilimumab; CRS 207 | Metastatic PDAC | +/− GVAX | Second-line or more | II | Recruiting |
| NCT02744287 | CAR-T cells | CAR-T cells directed against PSCA | Metastatic PDAC | None | Second-line | I/II | Recruiting |
| NCT03159819 | CAR-T cells | CAR-T cells directed against CLD18 | Advanced PDAC | None | Second-line | I | Recruiting |
| NCT03331562 | PD-1 | Pembrolizumab | Metastatic PDAC | +/− Vitamin D analog | Maintenance | II | Completed |
| NCT03376659 | PD-L1 | Durvalumab; CV301 | Metastatic PDAC | Capecitabine | Maintenance | I/II | Recruiting |
*
Status available on October 2020.
ALK, anaplastic lymphoma kinase; BRCA, breast cancer antigen; CAR-T, carbonic anhydrase 1; CLD18, claudin 18.2; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; MEK, mitogen-activated protein kinase; NRG1, neurogulin 1; PALB2, partner and localizer of BRCA2; PARP, poly ADP ribose polymerase; PDAC, pancreatic ductal adenocarcinoma; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; PSCA, prostate stem cell antigen.